pharmaphorum Podcast

Healthcare organisations are facing the simultaneous pressures of demonstrating ROI on AI investments, addressing clinician burnout, and satisfying compliance requirements. In a new pharmaphorum podcast, Dr Jay Anders, chief medical officer for Medicomp Systems, and also host of the Tell Me Where IT Hurts podcast, discusses why he believes that the only way organisations can solve all three of tho...

The cell culture media industry is currently experiencing significant growth, driven by the increasing demand for biopharmaceuticals, advancements in tissue engineering, and the rising number of research activities in cell biology. In a new pharmaphorum podcast, web editor Nicole Raleigh speaks with Brandon Pence, who was recently appointed President and COO of Fujifilm Biosciences, a company prev...

This year marks the 10th anniversary of Frontiers Health. In another episode of our limited Frontiers Health series of the pharmaphorum podcast, we speak with commercial strategy expert Pilar Fernández Hermida, founder of i-Expand, a commercial strategy firm focused on assisting Health Tech and Deeptech companies grow and monetise. Fernández Hermida shares her favourite memory from the conference’...

In a new pharmaphorum podcast, web editor Nicole Raleigh spoke with Anthony Cilento, vice president, data science & customer insights, at Bayer, in a post- Axtria Ignite 2025 discussion on the conference and agentic AI more generally. Cilento speaks to the advancement from GenAI to agentic AI, what’s changed for his own team in this regard and what’s required by way of a culture shift more gen...

This year marks the 10th anniversary of Frontiers Health. In another episode of our limited Frontiers Health series of the pharmaphorum podcast, we speak with founder, director, and global health advisor at D-Health Consulting, Roberta Sarno. Sarno is also director of the APAC Liver Disease Alliance, and consultant on digital health APAC policy at the American Telemedicine Association, as well as...

This year marks the 10th anniversary of Frontiers Health. In another episode of our limited Frontiers Health series of the pharmaphorum podcast, we speak with healthcare innovation consultant Gary Monk. Monk shares his favourite memory from the conference’s past decade, and discusses its ethos, as well as how his work at the moment aligns with that. Explore this Frontiers Health conversation and o...

Frontiers Health marks its 10th anniversary this year, celebrating a decade of innovation, collaboration, and the connections that drive progress.   In this episode of our Frontiers Health limited series of the pharmaphorum podcast, Deep Dive editor Eloise McLennan speaks with Aline Noizet, founder of Digital Health Connector  – a phrase that she says encapsulates both her personal mission and her...

In Donald Trump's first presidential term, he spoke a lot about "Most Favoured Nations" pricing for pharmaceuticals - that is, bringing the prices that Americans pay for drugs in line with prices paid around the world. In his first term, all that talk didn't amount to much. But this time around the pharma industry is taking the President much more seriously.   In today's pharmaphorum podcast, host...

Frontiers Health is back, and celebrating 10 years of innovation, conversation, and collaboration.   In this episode of our  Frontiers Health  limited series of the pharmaphorum podcast, Deep Dive editor Eloise McLennan speaks with Denise Silber, founder of Basil Strategies and Doctors 2.0.   Having spent more than two decades working at the intersection of healthcare professionals, patients, and...

Chronic myeloid leukaemia (CML) is a unique disorder in the rare disease sector because there are multiple approved therapies for patients and, in the US alone, the prevalence of CML is expected to triple by 2040. In a new pharmaphorum podcast, web editor Nicole Raleigh speaks with Amy Burroughs, CEO of Terns Pharmaceuticals, about available treatments for CML, the potential of allosteric TKIs, an...

In this episode of our  Frontiers Health  limited series of the pharmaphorum podcast, Deep Dive editor Eloise McLennan speaks with Steve Seuntjens, Partner at PHS Capital.   Seuntjens has long been focused on investing in innovation that puts the individual at the centre of health. For him, building companies is never easy – but it becomes meaningful when the outcome is more engaged people, improv...

When it comes to breaking down barriers, humour is vitally important, helping to do away with stigma when it comes – in particular – to pharma and health advertising. In a new pharmaphorum podcast, web editor Nicole Raleigh speaks with Brian Coane, health partner at creative agency Leith, who talks sensitivity, maximum impact, and overcoming the fear of getting it wrong. After all, dull ads can le...

Biotech finance has encountered what can arguably be termed the worst perfect storm in its history, and private investment in biopharma is in the midst of the longest drought. In a new pharmaphorum podcast, web editor Nicole Raleigh speaks with former surgeon and investment banker Ali Pashazadeh, CEO of Treehill, a strategic and financial advisory firm for the life sciences sector, in a conversati...

This year marks the 10th anniversary of Frontiers Health. In this episode of our  Frontiers Health  limited series of the pharmaphorum podcast, web editor Nicole Raleigh speaks with Unity Stoakes, president and co-founder of Startup Health and Advisory Board Member at The NeuroTech Collider Lab, University of California, Berkeley. Stoakes has spent 30+ years at the intersection of tech, science, a...

In a new pharmaphorum podcast, web editor Nicole Raleigh speaks with Hilary Eaton, a rare disease advocate and chief business officer at Profluent about AI-first protein design and its part in accelerating biomedicine. Eaton discusses her advocacy, gene editing, and how real-world evidence shows that AI scaling laws – which predict model performance based on size and computing power – apply to bio...

Characterising the behaviour of drugs in humans has historically required extensive clinical trials at considerable time and cost. So, any lab-derived early insight into how drugs will behave in human patients can make drug trials vastly more efficient. In this episode, the pharmaphorum podcast welcomes Adityo Prakash, founder and CEO of Verseon, a clinical-stage pharmaceutical company based in Fr...

This November marks a major milestone for health innovation as Frontiers Health celebrates its 10th anniversary.   To mark the occasion, pharmaphorum is proud to launch a special limited-edition podcast series, bringing you conversations with the people who’ve helped define the conference over the years – and those driving the next wave of innovation.   We’re kicking things off with a very special...

Managed Access Programs (or MAPs) enable mechanisms for patients with unmet medical needs to get access to new medications outside of the clinical trial setting and well before marketing authorisation and reimbursement in a patient's country. Also referred to as Expanded Access Programs and Early Access Programs, these programs are not limited to the US. In a new pharmaphorum podcast, web editor N...

When it comes to GLP-1 drugs like Ozempic, Wegovy, and Mounjaro there’s a lot to talk about, from the science behind the drugs and where it could go next to the cultural and societal implications of this highly effective treatment for diabetes, weight loss, and potentially much more. On today’s podcast editor-in-chief Jonah Comstock and Deep Dive editor Eloise McLennan forego the usual interview f...

Overall, the pharmaceutical industry is moving away from an approach where AI is task-driven, narrowly focused on a single, isolated problem. Instead, companies are embracing foundation models which, trained on very large and broad datasets, are versatile, and capable of tackling a range of complex challenges simultaneously. In a new pharmaphorum podcast, web editor Nicole Raleigh speaks with Bren...

Caris Life Sciences was founded in 2008 with a simple but powerful purpose – to realise the potential of precision medicine and help improve the lives of as many people as possible. In a post-ASCO pharmaphorum podcast, web editor Nicole Raleigh spoke with Eric Matthews, chief business officer at Caris Life Sciences, about advancing the frontier of cancer diagnostics and treatment with breakthrough...

When it comes to artificial intelligence, the tables are turning and there is a shift in considering it a hype to understanding that AI is a real necessity. And 2025 is becoming a turning point wherein practical, embedded AI begins to scale. In a new pharmaphorum podcast, web editor Nicole Raleigh speaks with Florian Schnappauf, VP, enterprise commercial strategy Europe, at Veeva Systems. The conv...

At ASCO 2025, Eisai presented data from its oncology portfolio, including in hepatocellular carcinoma and endometrial cancer. In a post-Congress conversation, web editor Nicole Raleigh spoke with Dr Corina Dutcus, senior vice president and oncology global clinical development lead at Eisai, who discussed the data and the company’s continued commitment to innovation in the oncological field. Tune i...

Metastatic pancreatic ductal adenocarcinoma (mPDAC) is a highly aggressive, lethal form of pancreatic cancer that accounts for more than 90% of pancreatic cancer cases. At ASCO 2025, Actuate gave an oral presentation on positive Phase 2 combination data for elraglusib, highlighting its potential to enhance anti-tumour activity by targeting key resistance pathways and immune mechanisms in previousl...

Melanoma is the fifth most common cancer in the UK, accounting for around 4% of all new cancer cases. While immunotherapy is a standard treatment for advanced melanoma patients, only about half of patients respond well, leaving the rest at risk of disease progression and metastases. In a new pharmaphorum podcast, web editor Nicole Raleigh speaks with Phillip L’Huillier, CEO of Scancell, about how...